Effects of Chitosan on xenograft models of melanoma in C57BL/6 mice and hepatoma formation in SCID mice

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 4867-4873

  Yeh, Ming Yang ^a   Wu, Ming Fang ^b   Shang, Hung Sheng ^c   Chang, Jin Biou ^c,d   Shih, Yung Luen ^e,f,g   Chen, Yung Liang ^d   Hung, Hsiao Fang ^h   Lu, Hsu Feng ^a   Yeh, Chun ^a   Wood, W Gibson ⁱ   Hung, Fang Ming ^j   Chung, Jing Gung ^k  

^a CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d YUANPEI UNIVERSITY   (Taiwan)

^e SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^h JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^j FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^k CHINA MEDICAL UNIVERSITY   (Taiwan)

more..

Author keywords

Chitosan; Hepatoma formation; Lung metastasis; Xenograft models

Indexed keywords

CHITOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; LIFESPAN; LIVER CELL CARCINOMA; LUNG METASTASIS; LUNG PARENCHYMA; MALE; MELANOMA; MELANOMA CELL; MOLECULAR WEIGHT; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

CHITOSAN; HEPATOMA FORMATION; LUNG METASTASIS; XENOGRAFT MODELS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CHELATING AGENTS; CHITOSAN; HETEROGRAFTS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, SCID; SURVIVAL RATE; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 84891365390     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. World Cancer Research Fund International: Series title. (http://www.wcrf.org/cancer-statistics/world-cancer-statistics.php)
2. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F and Capella G: Recent advances in cancer therapy: an overview. Curr Pharm Des 16: 3-10, 2010.
3. National Cancer Institute: Series title. (http://www.cancer.gov/ cancertopics)
4. Xu W, Towers AD, Li P and Collet JP: Traditional Chinese medicine in cancer care: perspectives and experiences of patients and professionals in China. Eur J Cancer Care (Engl) 15: 397-403, 2006.
5. Cui X, Wang Y, Kokudo N, Fang D and Tang W: Traditional Chinese medicine and related active compounds against hepatitis B virus infection. Biosci Trends 4: 39-47, 2010.
6. Wong R, Sagar CM and Sagar SM: Integration of Chinese medicine into supportive cancer care: a modern role for an ancient tradition. Cancer Treat Rev 27: 235-246, 2001.
7. Gai RY, Xu HL, Qu XJ, Wang FS, Lou HX, Han JX, Nakata M, Kokudo N, Sugawara Y, Kuroiwa C and Tang W: Dynamic of modernizing traditional Chinese medicine and the standards system for its development. Drug Discov Ther 2: 2-4, 2008.
8. Konkimalla VB and Efferth T: Evidence-based Chinese medicine for cancer therapy. J Ethnopharmacol 116: 207-210, 2008.
9. Rouget C: Des substances amylacees dans Ie tissue des animaux, specialement les Atricules (Chitine). Comp. Rend., pp. 792-795, 1859.
10. Hoppe-Seyler F: Ueber Chitosan und Zellulose. Ber. Deut. Chem. Gesell., pp. 3329-3331, 1894.
11. W. P and P. GC: Chitosan, a drug carrier for the 21st century: a review. STP Pharm. Sci., pp. 5-22, 2000.
12. Minke R and Blackwell J: The structure of alpha-chitin. J Mol Biol 120: 167-181, 1978.
13. van der Lubben IM, Verhoef JC, Borchard G and Junginger HE: Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 14: 201-207, 2001.
14. Kim S-K and Rajapakse N: Enzymatic production and biological activities of chitosan oligosaccharides (COS): A review. Carbohydrate Polymers 62: 357-368, 2005.
15. Vårum KM and Smidsrød O: Structure-property relationship in chitosans. In: In Polysaccharides: Structural Diversity and Functional Versatility. Dumitriu S (ed.). New York, NY, USA: Marcel Dekker, pp. 625-642, 2005.
16. Yin H, Du Y and Zhang J: Low molecular weight and oligomeric chitosans and their bioactivities. Curr Top Med Chem 9: 1546-1559, 2009.
17. Donnelly LE and Barnes PJ: Acidic mammalian chitinase - a potential target for asthma therapy. Trends Pharmacol Sci 25: 509-511, 2004.
18. Elias JA, Homer RJ, Hamid Q and Lee CG: Chitinases and chitinase-like proteins in T(H)2 inflammation and asthma. J Allergy Clin Immunol 116: 497-500, 2005.
19. Yi H, Wu LQ, Bentley WE, Ghodssi R, Rubloff GW, Culver JN and Payne GF: Biofabrication with chitosan. Biomacromolecules 6: 2881-2894, 2005.
20. Aiba S: Studies on chitosan: 4. Lysozymic hydrolysis of partially N-acetylated chitosans. Int J Biol Macromol 14: 225-228, 1992.
21. Hirano S, Seino H, Akiyama Y and Nonaka I: Biocompatibilityof chitosan by oral and intavenous administration. Polym Eng Sci 59: 897-901, 1988.
22. Lee KY, Ha WS and Park WH: Blood compatibility and biodegradability of partially N-acylated chitosan derivatives. Biomaterials 16: 1211-1216, 1995.
23. Muzzarelli RAA: Chitosan-Based Dietary Foods. Carbohydr Polym 29: 309-316, 1996.
24. Dodane V and Vilivalam VD: Pharmaceutical application of chitosan. Pharm Sci Technol Today 1: 246-253, 1998.
25. Kawada M, Hachiya Y, Arihiro A and Mizoguchi E: Role of mammalian chitinases in inflammatory conditions. Keio J Med 56: 21-27, 2007.
26. Zhu Z, Zheng T, Homer RJ, Kim YK, Chen NY, Cohn L, Hamid Q and Elias JA: Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 304: 1678-1682, 2004.
27. Rhoades J, Gibson G, Formentin K, Beer M and Rastall R: Inhibition of the adhesion of enteropathogenic Escherichia coli strains to HT-29 cells in culture by chito-oligosaccharides. Carbohydr Polym 642006.
28. Ribeiro MP, Espiga A, Silva D, Baptista P, Henriques J, Ferreira C, Silva JC, Borges JP, Pires E, Chaves P and Correia IJ: Development of a new chitosan hydrogel for wound dressing. Wound Repair Regen 17: 817-824, 2009.
29. Klokkevold PR, Vandemark L, Kenney EB and Bernard GW: Osteogenesis enhanced by chitosan (poly-N-acetyl glucosaminoglycan) in vitro. J Periodontol 67: 1170-1175, 1996.
30. R. J, K. S and T. Y: Growth and osteogenic differentiation of adipose- derived and bone marrow-derived stem cells on chitosan and chitooligosaccharide films. Carbohydrate Polymers 78: 873-878, 2009.
31. Shahabuddin M, Toyoshima T, Aikawa M and Kaslow DC: Transmission-blocking activity of a chitinase inhibitor and activation of malarial parasite chitinase by mosquito protease. Proc Natl Acad Sci USA 90: 4266-4270, 1993.
32. Muzarelli RAA: In Chitin. London, UK: Oxford Pergamon Press, pp. 262-270, 1977.
33. Nam KS, Kim MK and Shon YH: Inhibition of proinflammatory cytokine-induced invasiveness of HT-29 cells by chitosan oligosaccharide. J Microbiol Biotechnol 17: 2042-2045, 2007.
34. Shen KT, Chen MH, Chan HY, Jeng JH and Wang YJ: Inhibitory effects of chitooligosaccharides on tumor growth and metastasis. Food Chem Toxicol 47: 1864-1871, 2009.
35. Kim HM, Hong SH, Yoo SJ, Baek KS, Jeon YJ and Choung SY: Differential effects of chitooligosaccharides on serum cytokine levels in aged subjects. J Med Food 9: 427-430, 2006.
36. Oliveira EN, Jr., El Gueddari NE, Moerschbacher BM, Peter MG and Franco TT: Growth of phytopathogenic fungi in the presence of partially acetylated chitooligosaccharides. Mycopathologia 166: 163-174, 2008.
37. Yang L and Zaharoff DA: Role of chitosan co-formulation in enhancing interleukin-12 delivery and antitumor activity. Biomaterials 34: 3828-3836, 2013.
38. Chen G, Mi J, Wu X, Luo C, Li J, Tang Y and Li J: Structural features and bioactivities of the chitosan. Int J Biol Macromol 49: 543-547, 2011.
39. Nogueira DR, Tavano L, Mitjans M, Perez L, Infante MR and Vinardell MP: In vitro antitumor activity of methotrexate via pH-sensitive chitosan nanoparticles. Biomaterials 34: 2758-2772, 2013.